BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24227760)

  • 21. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
    Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.
    Gaisina IN; Tueckmantel W; Ugolkov A; Shen S; Hoffen J; Dubrovskyi O; Mazar A; Schoon RA; Billadeau D; Kozikowski AP
    ChemMedChem; 2016 Jan; 11(1):81-92. PubMed ID: 26592932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Design, synthesis, and biological activities of histone deacetylase inhibitors with diketo ester as zinc binding group].
    Lu H; Su H; Yang B; You QD
    Yao Xue Xue Bao; 2011 Mar; 46(3):293-8. PubMed ID: 21626783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives as Raf and Histone Deacetylases Dual Inhibitors.
    Chen X; Gong G; Chen X; Song R; Duan M; Qiao R; Jiao Y; Qi J; Chen Y; Zhu Y
    Chem Pharm Bull (Tokyo); 2019; 67(10):1116-1122. PubMed ID: 31582631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities.
    Zhao N; Yang F; Han L; Qu Y; Ge D; Zhang H
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32046013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities.
    Yang F; Peng S; Li Y; Su L; Peng Y; Wu J; Chen H; Liu M; Yi Z; Chen Y
    Org Biomol Chem; 2016 Feb; 14(5):1727-35. PubMed ID: 26732459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity.
    Ding Q; Liu C; Zhao C; Dong H; Xu Q; James Chou C; Zhang Y
    Bioorg Chem; 2020 Nov; 104():104235. PubMed ID: 32896808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
    Aboeldahab AMA; Beshr EAM; Shoman ME; Rabea SM; Aly OM
    Eur J Med Chem; 2018 Feb; 146():79-92. PubMed ID: 29396364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor.
    Zhou Y; Dun Y; Fu H; Wang L; Pan X; Yang X; Fang H
    Chem Biol Drug Des; 2017 Nov; 90(5):936-942. PubMed ID: 28489276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
    Xie R; Li Y; Tang P; Yuan Q
    Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
    Chen X; Zhao S; Li H; Wang X; Geng A; Cui H; Lu T; Chen Y; Zhu Y
    Eur J Med Chem; 2019 Apr; 168():110-122. PubMed ID: 30802729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
    Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity.
    Ibrahim TS; Sheha TA; Abo-Dya NE; AlAwadh MA; Alhakamy NA; Abdel-Samii ZK; Panda SS; Abuo-Rahma GEA; Mohamed MFA
    Bioorg Chem; 2020 Jun; 99():103797. PubMed ID: 32247939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
    Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
    Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors.
    Chen Y; Zhang L; Zhang L; Jiang Q; Zhang L
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):425-436. PubMed ID: 33445997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
    Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
    J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.